[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tibet Autonomous Region People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100643117","key-diagnostic--therapeutic-technologies-for-severe-acute-high-altitude-disease-sahad-integration-and-application-100643117",false,"NCT07639931","Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and Application","Integration and Application Demonstration of Key Diagnosis and Treatment Technologies for Severe Acute High Altitude Disease","SAHAD","Inclusion Criteria:\n\n1. Meeting the diagnostic criteria for severe acute mountain sickness (including high-altitude pulmonary edema \\[HAPE\\] and high-altitude cerebral edema \\[HACE\\]).\n2. Aged 18 to 75 years.\n3. Rapid ascent to an altitude above 2500 m within 72 hours prior to onset.\n\nExclusion Criteria:\n\n1. History of severe cardiopulmonary diseases.\n2. Pregnant women, patients with psychiatric disorders, inability to cooperate with treatment or follow-up, and patients with an expected survival of less than 6 months.\n3. Patients with malignant tumors, severe hepatic or renal insufficiency, or immune system diseases requiring immunosuppressive therapy.",true,"ALL","18 Years","75 Years",{"count":22,"type":23},3035,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to establish a key technical system for the diagnosis and treatment of severe acute mountain sickness based on real-world clinical data in Xizang, develop standardized diagnosis and treatment protocols and an intelligent early warning model, validate its efficacy through multicenter studies, and innovate diagnostic and therapeutic technologies. It will achieve early identification, precise diagnosis, standardized treatment, and intelligent warning of severe acute mountain sickness, comprehensively improving its prevention, control and treatment success rate.",[29,30],"Severe High Altitude Pulmonary Edema","Severe High Altitude Cerebral Edema",[32,33,34,35],"High altitude","Key Diagnostic","Therapeutic Technologies","Severe Acute High Altitude Disease (SAHAD)","NOT_YET_RECRUITING","2026-06-07",{"date":39,"type":40},"2026-06-10","ACTUAL",{"date":42,"type":23},"2026-07-01",{"date":44,"type":23},"2028-12-31",{"name":46,"class":47},"Tibet Autonomous Region People's Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100640422","high-altitude-polycythemia-study-100640422","NCT07600086","High-Altitude Polycythemia Study","Clinical Study on the Therapeutic Effect of Non-Invasive Ventilator in the Treatment of High-Altitude Polycythemia","NIV-HAPC","Inclusion Criteria:\n\n1. Diagnosed with high-altitude polycythemia (HAPC).\n2. Aged 18 years or older, with no gender restriction.\n3. Voluntarily participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Disturbance of consciousness.\n2. Inability to independently clear airway secretions, with the risk of aspiration.\n3. Severe upper gastrointestinal bleeding.\n4. Hemodynamic instability.\n5. Upper airway obstruction.\n6. Un drained pneumothorax or mediastinal emphysema.\n7. Conditions that prevent mask wearing, such as facial trauma or deformity.\n8. Patient non-compliance.",{"count":58,"type":23},70,[26],"This study aims to evaluate the clinical efficacy of non-invasive ventilation (NIV) in treating patients with high-altitude polycythemia (HAPC).\n\nParticipants will be enrolled according to the international diagnostic criteria for high-altitude polycythemia. The study will use both retrospective cohort and prospective study methods.\n\nAll participants will receive standard basic care. In addition, the intervention group will receive non-invasive ventilation treatment using either BiPAP or CPAP mode.\n\nKey measurements, including routine blood tests, liver function, renal function, uric acid, blood lipid profile, electrocardiogram and echocardiography, will be collected as primary and secondary outcome measures to assess the effects of the treatment.",[62,63],"High-altitude Polycythemia","HAPC","2026-05-14",{"date":66,"type":40},"2026-05-20",{"date":68,"type":23},"2026-05",{"date":70,"type":23},"2028-12",{"name":46,"class":47},""]